Palatin Technologies, Inc. Board of Directors

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Dr. Carl Spana Ph.D.

Dr. Carl Spana Ph.D.

Co-Founder, President, CEO & Director

Mr. Robert Jordan

Mr. Robert Jordan

Senior Vice President of Program Operations

Mr. James E. Hattersley

Mr. James E. Hattersley

Senior Vice President of Business Development

Burns McClellan

Burns McClellan

Vice President of Investor Relations

Mr. John Dodd Ph.D.

Mr. John Dodd Ph.D.

Senior Vice President of Preclinical Development

Mr. Stephen T. Wills CPA, MST

Mr. Stephen T. Wills CPA, MST

CFO, COO, Executive VP, Treasurer & Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.